We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+31.31%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.59B
AUM Growth
+$94.3M
Cap. Flow
-$331M
Cap. Flow %
-12.8%
Top 10 Hldgs %
60.43%
Holding
115
New
13
Increased
19
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$58.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
3
PYPL icon
PayPal
PYPL
+$20.8M
4
ARGX icon
argenx
ARGX
+$20.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$12.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$70M
2
NVDA icon
NVIDIA
NVDA
+$34.8M
3
AVTR icon
Avantor
AVTR
+$19.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$17M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.99%
2 Consumer Discretionary 25.71%
3 Communication Services 1.46%
4 Technology 1.19%
5 Financials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
76
Adaptive Biotechnologies
ADPT
$3.54B
$4.49M 0.17%
150,000
– –
KRYS icon
77
Krystal Biotech
KRYS
$10.7B
$4.43M 0.17%
80,000
-70,000
-47% -$3.43M
YI
78
111 Inc
YI
$33.4M
$4.38M 0.17%
65,000
– –
FATE icon
79
CALL
Fate Therapeutics
FATE
$269M
$3.91M 0.15%
+200,000
New +$3.18M
ALEC icon
80
Alector
ALEC
$171M
$3.88M 0.15%
225,000
– –
STML
81
DELISTED
Stemline Therapeutics, Inc.
STML
$3.83M 0.15%
360,000
– –
REAL icon
82
The RealReal
REAL
$1.42B
$3.77M 0.15%
200,000
-365,000
-65% -$6.99M
KRTX
83
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.77M 0.15%
+50,000
New +$2.19M
CYCN icon
84
Cyclerion Therapeutics
CYCN
$14.9M
$3.7M 0.14%
68,079
– –
SGMO
85
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.39M 0.13%
405,000
– –
DOYU
86
DouYu International Holdings
DOYU
$139M
$3.39M 0.13%
40,000
– –
NTLA icon
87
Intellia Therapeutics
NTLA
$1.49B
$2.93M 0.11%
+199,700
New +$2.78M
VKTX icon
88
Viking Therapeutics
VKTX
$3.88B
$2.81M 0.11%
350,000
– –
AKBA icon
89
Akebia Therapeutics
AKBA
$333M
$2.69M 0.1%
425,000
– –
CRIS icon
90
Curis
CRIS
$9.67M
$2.55M 0.1%
+3,750
New +$2.72M
KLDO
91
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$2.51M 0.1%
500,500
-400,000
-44% -$2.54M
SYRE icon
92
Spyre Therapeutics
SYRE
$8.38B
$2.29M 0.09%
12,000
– –
TWST icon
93
Twist Bioscience
TWST
$5.29B
$2.1M 0.08%
100,000
– –
AXLA
94
DELISTED
Axcella Health Inc. Common Stock
AXLA
$1.8M 0.07%
18,000
– –
IRWD icon
95
Ironwood Pharmaceuticals
IRWD
$604M
$1.47M 0.06%
110,532
– –
KDNY
96
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.18M 0.05%
200,000
– –
ACET icon
97
Adicet Bio
ACET
$76.6M
– –
-4,464
Closed -$4.42M
ALLO icon
98
Allogene Therapeutics
ALLO
$580M
– –
-100,000
Closed -$2.73M
BABA icon
99
CALL
Alibaba
BABA
$276B
– –
-100,000
Closed -$16.7M
BAC icon
100
CALL
Bank of America
BAC
$435B
– –
-3,000,000
Closed -$87.5M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2019 Portfolio in Review

As of Q4 2019, Artal Group held 115 positions worth $2.59B, up 3.8% from $2.49B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group withdrew a net $331M in Q4 2019, closing 19 positions and reducing 20 holdings. Its most notable exit was Medicines Co, an estimated $70M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Artal Group opened a new position in BioNTech worth $89M.

  • Artal Group's largest Q4 2019 buy was BioNTech: 2,628,130 shares worth $89M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2019, an estimated $29.9M increase.
  • Artal Group's biggest Q4 2019 reduction was Avantor, cutting an estimated $19.9M.
  • Artal Group fully exited Medicines Co in Q4 2019, selling an estimated $70M.
  • Artal Group's ten largest holdings make up 60% of its $2.59B portfolio in Q4 2019.
  • Artal Group opened 13 new positions and closed 19 in Q4 2019.
  • Artal Group's portfolio value rose 3.8% quarter-over-quarter to $2.59B.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.